Forbes July 11, 2024
Over the past two decades, genome sequencing–unscrambling the building blocks of DNA that form our genetic code–has become an essential tool in medicine. It helped expedite the development Covid-19 vaccines and it’s led to new ways to treat cancer. It’s also a crucial element of precision medicine–tailoring disease treatment to each patient’s unique biology.
With its DNA sequencing platform Aviti, San Diego-based startup Element Biosciences is among the many players in this R&D sandbox. Today, the company announced that it has raised a $277 million series D investment at a $1.03 billion valuation. That new money brings the company’s total funding to date to $680 million. The round was led by Wellington Management Private Investment, with participation from Samsung Electronics,...
Today's Sponsors
Today's Sponsor